TriSalus Life Sciences, Inc.
TLSI
$4.73
$0.368.24%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -2.92% | 59.85% | 57.38% | 52.27% | 41.97% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -2.92% | 59.85% | 57.38% | 52.27% | 41.97% |
| Cost of Revenue | -17.73% | 44.90% | 89.84% | 97.59% | 53.96% |
| Gross Profit | -0.04% | 62.43% | 52.25% | 45.86% | 39.85% |
| SG&A Expenses | 7.38% | 4.10% | 24.23% | 28.71% | 5.89% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.93% | 4.01% | 27.92% | 19.35% | -9.01% |
| Operating Income | -14.76% | 56.85% | -3.15% | 10.30% | 37.21% |
| Income Before Tax | 114.88% | 3.52% | -349.88% | -91.70% | 21.46% |
| Income Tax Expenses | -20.00% | 100.00% | 266.67% | -142.86% | 66.67% |
| Earnings from Continuing Operations | 114.83% | 3.51% | -350.65% | -91.32% | 21.44% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 114.83% | 3.51% | -350.65% | -91.32% | 21.44% |
| EBIT | -14.76% | 56.85% | -3.15% | 10.30% | 37.21% |
| EBITDA | -15.64% | 57.43% | -3.44% | 10.19% | 37.75% |
| EPS Basic | 107.57% | 47.33% | -693.54% | -6.94% | 35.30% |
| Normalized Basic EPS | 66.54% | 70.78% | -72.31% | 63.84% | 15.27% |
| EPS Diluted | 107.54% | 47.33% | -693.54% | -6.94% | 35.06% |
| Normalized Diluted EPS | 66.54% | 70.78% | -72.31% | 63.84% | 15.27% |
| Average Basic Shares Outstanding | 83.38% | 70.03% | 62.47% | 38.01% | 22.31% |
| Average Diluted Shares Outstanding | 83.38% | 70.03% | 62.47% | 38.01% | 22.31% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |